AU Patent

AU2025203339A1 — Therapeutic Uses of Tirzepatide

Assigned to Eli Lilly and Co · Expires 2025-05-29 · 1y expired

What this patent protects

The present invention relates to methods for treating, preventing or delaying disorders relating to cognition, such as cognitive decline, cognitive impairment or dementia. The present invention relates to method for treating, preventing or delaying 5 heart failure, such as HFp…

USPTO Abstract

The present invention relates to methods for treating, preventing or delaying disorders relating to cognition, such as cognitive decline, cognitive impairment or dementia. The present invention relates to method for treating, preventing or delaying 5 heart failure, such as HFpEF or HFrEF.

Drugs covered by this patent

Patent Metadata

Patent number
AU2025203339A1
Jurisdiction
AU
Classification
—
Expires
2025-05-29
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.